Research map: Budigalimab: a viable option for patients with advanced solid tumors

Back to the article

Papers in this map

  1. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors · Bertrand Routy · 2017 · 5713 citations · Cited by this paper
  2. Advancements in longevity pharmacology research – are we finally seeing clinical progression? · 2026 · Related
  3. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade · Mark Ayers · 2017 · 3986 citations · Cited by this paper
  4. Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis · 2025 · Related
  5. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer · Laura Mezquita · 2018 · 982 citations · Cited by this paper
  6. Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a) · 2025 · Related
  7. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study · Marina Chiara Garassino · 2023 · 725 citations · Cited by this paper
  8. The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates · 2026 · Related
  9. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab · Suzanne Louise Topalian · 2019 · 645 citations · Cited by this paper
  10. Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates · 2026 · Related
  11. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study · Silvia Novello · 2023 · 563 citations · Cited by this paper
  12. Assessing the clinical progress of muvalaplin for reducing lipoprotein(a) · 2025 · Related
  13. Development of Immunotherapy Combination Strategies in Cancer · Timothy Anthony Yap · 2021 · 332 citations · Cited by this paper
  14. Menin inhibitors for adult acute myeloid leukemia: 2025 update · 2025 · Related
  15. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study · Fiona Helen Blackhall · 2021 · 280 citations · Cited by this paper
  16. Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? · 2026 · Related
  17. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? · Keith M. Kerr · 2015 · 272 citations · Cited by this paper
  18. Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? · 2026 · Related
  19. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis · M. Duruisseaux · 2018 · 226 citations · Cited by this paper
  20. A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug · 2026 · Related
  21. PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: Updated Survival Data · Pedro Nazareth Aguiar · 2017 · 206 citations · Cited by this paper
  22. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer · Manash Shankar Chatterjee · 2016 · 173 citations · Cited by this paper
  23. A Guide to Rational Dosing of Monoclonal Antibodies · Shuang Bai · 2012 · 165 citations · Cited by this paper
  24. The clinical utility of tumor mutational burden in non-small cell lung cancer · Laurent Greillier · 2018 · 124 citations · Cited by this paper
  25. Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys · Maya Kaushal Leabman · 2013 · 111 citations · Cited by this paper
  26. The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development · Arielle Elkrief · 2025 · 80 citations · Cited by this paper
  27. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial · Sreya Duttagupta · 2026 · 70 citations · Cited by this paper
  28. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications · Mauricio Burotto · 2023 · 55 citations · Cited by this paper
  29. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors · Ole V. Gjoerup · 2020 · 52 citations · Cited by this paper
  30. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial · E. Felip · 2025 · 39 citations · Cited by this paper
  31. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study · Erika Paige Hamilton · 2020 · 28 citations · Cited by this paper
  32. IL-1β mediates the induction of immune checkpoint regulators IDO1 and PD-L1 in lung adenocarcinoma cells · Afshan Fathima Nawas · 2023 · 26 citations · Cited by this paper
  33. Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) · Sneha Berry · 2019 · 23 citations · Cited by this paper
  34. Fc Effector Function of Immune Checkpoint Blocking Antibodies in Oncology · Romane Martineau · 2024 · 23 citations · Cited by this paper
  35. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma · Antoîne Italiano · 2021 · 19 citations · Cited by this paper
  36. Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab · Stacie L. Lambert · 2022 · 19 citations · Cited by this paper
  37. First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors · Toshio Shimizu · 2024 · 13 citations · Cited by this paper
  38. Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181) · John D. Powderly · 2020 · 12 citations · Cited by this paper
  39. Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study · Moti N. Ramgopal · 2025 · 12 citations · Cited by this paper

Source: OpenAlex (CC0)